PMID

Data

Article Title

Organization

Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.

Eisai

Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.

Eisai

Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.

Neurocrine Biosciences

Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.

Salk Institute

Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.

Dupont Pharmaceuticals

Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical And Public Health Institute

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.

Pharmaceutical Research Institute

2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.

Bristol-Myers Squibb Pharmaceutical Research Institute

Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.

Takeda Pharmaceutical

Synthesis and anticholinesterase activities of novel 1,3,4-thiadiazole based compounds.

University Of Life Sciences